Uncategorized
Lucentis recommended for EU approval for sixth indication
The Committee for Medicinal Products for Human Use has recommended the approval of Lucentis in the European Union for the treatment of patients with visual impairment due to choroidal neovascularization not caused by neovascular age-related macular degeneration or myopic choroidal neovascularization, Novartis announced.The indication would be the sixth approved indication in Europe for use of Lucentis (ranibizumab).